TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

Benzinga Newsdesk www.benzinga.com Neutral 67.6%

Neg 0% Neu 67.6% Pos 0%

TD Cowen analyst Tara Bancroft initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating.

Comments

No comments yet. Be the first!